NASDAQ:EVAX - Nasdaq - US29970R3030 - ADR - Currency: USD
NASDAQ:EVAX (6/13/2025, 4:30:02 PM)
2.77
-0.2 (-6.73%)
The current stock price of EVAX is 2.77 USD. In the past month the price increased by 66.87%. In the past year, price decreased by -82.13%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.61 | 337.52B | ||
AMGN | AMGEN INC | 14.22 | 158.74B | ||
GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
NTRA | NATERA INC | N/A | 22.58B | ||
BIIB | BIOGEN INC | 8.26 | 19.14B | ||
INSM | INSMED INC | N/A | 17.98B |
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
EVAXION A/S
Dr. Neergaards Vej 5F
Hoersholm 1260 DK
CEO: Lars Staal Webner
Employees: 46
The current stock price of EVAX is 2.77 USD. The price decreased by -6.73% in the last trading session.
The exchange symbol of EVAXION A/S is EVAX and it is listed on the Nasdaq exchange.
EVAX stock is listed on the Nasdaq exchange.
8 analysts have analysed EVAX and the average price target is 32.56 USD. This implies a price increase of 1075.27% is expected in the next year compared to the current price of 2.77. Check the EVAXION A/S stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EVAXION A/S (EVAX) has a market capitalization of 17.50M USD. This makes EVAX a Nano Cap stock.
EVAXION A/S (EVAX) currently has 46 employees.
EVAXION A/S (EVAX) has a support level at 2.97 and a resistance level at 3.14. Check the full technical report for a detailed analysis of EVAX support and resistance levels.
The Revenue of EVAXION A/S (EVAX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EVAX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EVAX does not pay a dividend.
EVAXION A/S (EVAX) will report earnings on 2025-08-12.
EVAXION A/S (EVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.37).
The outstanding short interest for EVAXION A/S (EVAX) is 0.25% of its float. Check the ownership tab for more information on the EVAX short interest.
ChartMill assigns a technical rating of 4 / 10 to EVAX. When comparing the yearly performance of all stocks, EVAX is a bad performer in the overall market: 80.49% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to EVAX. Both the profitability and financial health of EVAX have multiple concerns.
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -1.37. The EPS increased by 95.02% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -84.65% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to EVAX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -511.24% and a revenue growth -100% for EVAX